Long-acting muscarinic antagonist and long-acting β₂-agonist combination for the treatment of maintenance therapy-naive patients with chronic obstructive pulmonary disease: a narrative review.

ABSTRACT: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Faster lung function impairment occurs earlier in the disease, particularly in mild-to-moderate COPD, highlighting the need for early and effective targeted interventions. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 report recommends initial pharmacologic treatment with a long-acting muscarinic antagonist (LAMA) and long-acting β₂-agonist (LABA) combination in group B (0 or 1 moderate exacerbation not leading to hospitalization, modified Medical Research Council score of ⩾2, and COPD Assessment Test™ score of ⩾10) and E (⩾2 moderate exacerbations or ⩾1 exacerbation leading to hospitalization and blood eosinophil count <300 cells/µL) patients. In random

SUBMITTER: Buhl R 

PROVIDER: S-EPMC11456191 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature